Navigation Links
Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008
Date:7/29/2008

y and with partners, including Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, clinical trials and studies may not proceed at the time or in the manner Arena expects or at all, the results of clinical trials or preclinical studies may not be predictive of future results, Arena's ability to partner lorcaserin, APD125, APD791 or other of its compounds or programs, the timing, success and cost of Arena's research, out-licensing endeavors and clinical trials, Arena's ability to obtain additional financing, Arena's ability to obtain and defend its patents, the timing and receipt of payments and fees, if any, from Arena's collaborators, and Arena's ability to redeem with common stock any outstanding shares of its series B convertible preferred stock. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward- looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable la
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
2. ThreeWire Expands Presence in the Pharmaceutical Arena
3. Arena Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
4. Arena Pharmaceuticals Announces First Quarter 2008 Financial Results
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
7. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008
8. Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
9. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
10. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
11. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... January 23, 2015 Portal Solutions , ... workplaces on Microsoft Office 365 and SharePoint platforms , ... Award program for being one of the region’s fastest-growing mid-sized ... employee growth. , “To be recognized a second year ...
(Date:1/22/2015)... today announces the firm brokered a long-term lease totaling 202,492 ... company, at Two Ledgemont Center in Lexington, Massachusetts ... and Brian Cohen , senior vice president, represented Shire ... Hayden Ave. Photo - http://photos.prnewswire.com/prnh/20150122/170765 ...
(Date:1/22/2015)... San Diego, California (PRWEB) January 22, 2015 ... R Promotional Offer to their comprehensive portfolio of ... Offer allows customers to purchase a Centrifuge 5424/5424 R ... Pipette Bundle of either Eppendorf Research plus or Eppendorf ...
(Date:1/22/2015)... 2015 Diagenode, Inc., a leading ... Bioruptor® and complete solutions for epigenetics research, recently ... alleviating the need for manual processing. The new ... ChIP of histones or transcription factors and a ...
Breaking Biology Technology:Washington SmartCEO Announces Portal Solutions as 2015 Future 50 Award Winner Second Year in a Row 2Washington SmartCEO Announces Portal Solutions as 2015 Future 50 Award Winner Second Year in a Row 3Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2
... - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ: ONCY ) ... for the year ended December 31, 2008. , "In ... said Dr. Brad Thompson, President and CEO of Oncolytics. ... by interim results reported in our US and UK ...
... Venture: QPTEDMONTON, March 4 /PRNewswire-FirstCall/ - Quest PharmaTech ... pharmaceutical company developing and commercializing products for the ... results from a study designed to investigate the ... (PDT) used in combination with immunotherapeutic agents in ...
... N.C., March 4 Micell Technologies announced today ... Micell Rapid Absorption Polymer DES System" during the ... on March 5, 2009. MiStent(TM), a Drug-Eluting Stent ... coating that delivers the potential benefits of the ...
Cached Biology Technology:Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008 2Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008 3Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008 4Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008 5Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008 6Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008 7Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008 8Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008 9Quest PharmaTech Announces Results Showing its Photosensitizer, SL052, is an Effective Immuno-Stimulant when combined with Immunotherapy for the Removal of Solid Tumors 2Quest PharmaTech Announces Results Showing its Photosensitizer, SL052, is an Effective Immuno-Stimulant when combined with Immunotherapy for the Removal of Solid Tumors 3Micell Technologies' Rapid Absorption Polymer DES System to be Presented at CRT 2009 2
(Date:12/11/2014)...  That blood pressure plays a role in human health has ... term for high blood pressure – was first described as ... that,s used in measuring blood pressure was invented in 1896. ... hypertension, its triggers and its effects. In fact, recent findings ...
(Date:12/10/2014)... You,ve been here before: you desperately need to sign into your ... the answer to your secret question. What,s your dog,s birthday? Who ... Labs , a digital infrastructure security company, launches the ... comes with usernames, passwords and PINs – 1U TM ...
(Date:12/10/2014)... 2014  Wake Forest Baptist Medical Center today announced plans for ... Funding for this $50 million capital project is part of ... summer. The medical education building will be ... complex, adjacent to 525@vine in Wake Forest Innovation Quarter. Construction ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... protein associated with Alzheimer's disease in the brain of ... between neuronal death and proteins previously associated with cancer. ... Feany, and colleagues from Brigham and Women's Hospital, Harvard ... the brain generally do not divide. It is therefore ...
... that tend and harvest gardens of fungus have ... their crops: antibiotic-producing bacteria that the insects harbor ... journal Science, an international team led by University ... and ancient nature of this mutualistic relationship. ...
... pollution is a serious and growing environmental problem, especially ... Georgia had, several years ago, used genetic techniques to ... sites. , There was a problem, however. The arsenic ... the plant, making it difficult to harvest for safe ...
Cached Biology News:Study reveals classic symbiotic relationship between ants, bacteria 2Study reveals classic symbiotic relationship between ants, bacteria 3Researchers discover way to transport environmental arsenic to plant leaves in new clean-up strategy 2
Anti-Rat KAPPA/LAMBDA:HRP, Clone MARK-1/MARL-15, Monoclonal Antibody...
MOUSE ANTI RAT KAPPA/LAMBDA:HRP Immunogen: MARK-1: Rat kappa light chains (IR202 and IR968)MARL-15: Rat lambda light chains (RH58, IR31)...
Request Info...
Request Info...
Biology Products: